KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Finished Goods (2016 - 2025)

Boston Scientific's Finished Goods history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Finished Goods rose 2.84% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 2.84%, while the annual FY2025 figure was $1.8 billion, 2.84% up from the prior year.
  • Finished Goods for Q4 2025 was $1.8 billion at Boston Scientific, up from $1.8 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $1.8 billion in Q4 2025 and bottomed at $921.0 million in Q1 2021.
  • The 5-year median for Finished Goods is $1.4 billion (2023), against an average of $1.4 billion.
  • The largest annual shift saw Finished Goods decreased 7.06% in 2021 before it surged 32.43% in 2023.
  • A 5-year view of Finished Goods shows it stood at $1.0 billion in 2021, then increased by 13.8% to $1.2 billion in 2022, then surged by 31.26% to $1.5 billion in 2023, then grew by 16.98% to $1.8 billion in 2024, then rose by 2.84% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Finished Goods are $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025).